Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 44

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 44
---
 Fund, LLC (“ Partners GP I ”) is the ultimate general partner of PIF I, and Partners Innovation Fund II, LLC (“ Partners GP II ”) is the ultimate general partner of PIF II. Julius Knowles, a member of our Board, is a partner of each of Partners GP and Partners GP II, and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Partners Entities. The address of each of the Partners Entities is 215 First Street, Suite 500, Cambridge, Massachusetts 02142. (14) Includes 36,586 shares issuable upon the exercise of options granted to Mr. Nussbaum that are exercisable within 60 days of April 11, 2025. (15) Consists of shares issuable upon the exercise of options granted to Dr. Seth that are exercisable within 60 days of April 11, 2025. (16) Consists of (i) 6,683,980 shares of common stock and (ii) 2,111,056 shares issuable upon the exercise of options granted to our current executive officers and directors that are exercisable within 60 days of April 11, 2025. The shares held by the Pontifax Entities referred to in footnote (2) above of which Mr. Kariv and Mr. Nussbaum may be deemed to share voting and investment power with respect to have been counted once for purposes of calculating the number of shares beneficially owned by all current executive officers and directors as a group. 28

TABLE OF CONTENTS

EXECUTIVE OFFICERS The following table sets forth, for our executive officers, their ages and position held with us as of the date of this Proxy Statement:

| Name                 | ​ | ​ | Age | ​ | ​ | Principal Position                | ​ |
| Jasbir Seehra, Ph.D. | ​ | ​ |  69 | ​ | ​ | Chief Executive Officer and Chair | ​ |
| Keith Regnante       | ​ | ​ |  55 | ​ | ​ | Chief Financial Officer           | ​ |
| Yung Chyung, M.D.    | ​ | ​ |  49 | ​ | ​ | Chief Medical Officer             | ​ |
| Christopher Rovaldi  | ​ | ​ |  51 | ​ | ​ | Chief Operating Officer           | ​ |

Biographical information for Dr. Seehra is presented above under the caption